Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy
Abstract Background The tumor microenvironment is associated with prognosis in advanced non‐small cell lung carcinoma (NSCLC). The aim of this study was to explore the relationship between blood T cell diversity and survival of patients treated with pemetrexed‐based chemotherapy for nonsquamous NSCL...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-04-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.13771 |
id |
doaj-3c6485b0183e418680c2fa381e51666b |
---|---|
record_format |
Article |
spelling |
doaj-3c6485b0183e418680c2fa381e51666b2021-04-02T04:50:28ZengWileyThoracic Cancer1759-77061759-77142021-04-01127997100510.1111/1759-7714.13771Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapyLi Qian0Zhang Zhaohui1Xu Yaping2Liu Zhentian3Liu Zhentao4Wang Qiqi5Gu Yangchun6Liu Yan'e7Yin Wencheng8Yi Fumei9Yao Yanhong10Cao Baoshan11Liang Li12Department of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaAbstract Background The tumor microenvironment is associated with prognosis in advanced non‐small cell lung carcinoma (NSCLC). The aim of this study was to explore the relationship between blood T cell diversity and survival of patients treated with pemetrexed‐based chemotherapy for nonsquamous NSCLC. Methods This prospective clinical study enrolled 26 patients with advanced NSCLC treated with 4–6 cycles of first‐line pemetrexed combined with platinum‐based therapy. The complementarity‐determining region 3 (CDR3) located in the T cell receptor beta chain (TCR β chain) was captured and deeply sequenced using next‐generation sequencing (NGS) technology, and the correlation between TCR changes and efficacy after chemotherapy was analyzed. Results Patients with an inferior quarter diversity index showed a significantly shorter progression‐free survival (PFS) than the others (median, 5.0 months vs. 8.1 months, P = 0.014). After two cycles of chemotherapy, the TCR diversity was significantly higher than the baseline (P = 0.034). Just as with the baseline, patients with an inferior quarter diversity index at the endpoint of cycle 2 showed a shorter progression‐free survival (PFS) than the others (median, 5.0 months vs. 8.4 months, P = 0.024). Conclusions In advanced NSCLC patients treated with first‐line pemetrexed combined with platinum, the low level of blood TCR diversity at baseline with an endpoint of two cycles of chemotherapy was correlated with a poor prognosis.https://doi.org/10.1111/1759-7714.13771Advanced non‐small cell lung carcinomaT cell diversitytumor microenvironment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Li Qian Zhang Zhaohui Xu Yaping Liu Zhentian Liu Zhentao Wang Qiqi Gu Yangchun Liu Yan'e Yin Wencheng Yi Fumei Yao Yanhong Cao Baoshan Liang Li |
spellingShingle |
Li Qian Zhang Zhaohui Xu Yaping Liu Zhentian Liu Zhentao Wang Qiqi Gu Yangchun Liu Yan'e Yin Wencheng Yi Fumei Yao Yanhong Cao Baoshan Liang Li Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy Thoracic Cancer Advanced non‐small cell lung carcinoma T cell diversity tumor microenvironment |
author_facet |
Li Qian Zhang Zhaohui Xu Yaping Liu Zhentian Liu Zhentao Wang Qiqi Gu Yangchun Liu Yan'e Yin Wencheng Yi Fumei Yao Yanhong Cao Baoshan Liang Li |
author_sort |
Li Qian |
title |
Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy |
title_short |
Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy |
title_full |
Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy |
title_fullStr |
Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy |
title_full_unstemmed |
Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy |
title_sort |
blood t cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy |
publisher |
Wiley |
series |
Thoracic Cancer |
issn |
1759-7706 1759-7714 |
publishDate |
2021-04-01 |
description |
Abstract Background The tumor microenvironment is associated with prognosis in advanced non‐small cell lung carcinoma (NSCLC). The aim of this study was to explore the relationship between blood T cell diversity and survival of patients treated with pemetrexed‐based chemotherapy for nonsquamous NSCLC. Methods This prospective clinical study enrolled 26 patients with advanced NSCLC treated with 4–6 cycles of first‐line pemetrexed combined with platinum‐based therapy. The complementarity‐determining region 3 (CDR3) located in the T cell receptor beta chain (TCR β chain) was captured and deeply sequenced using next‐generation sequencing (NGS) technology, and the correlation between TCR changes and efficacy after chemotherapy was analyzed. Results Patients with an inferior quarter diversity index showed a significantly shorter progression‐free survival (PFS) than the others (median, 5.0 months vs. 8.1 months, P = 0.014). After two cycles of chemotherapy, the TCR diversity was significantly higher than the baseline (P = 0.034). Just as with the baseline, patients with an inferior quarter diversity index at the endpoint of cycle 2 showed a shorter progression‐free survival (PFS) than the others (median, 5.0 months vs. 8.4 months, P = 0.024). Conclusions In advanced NSCLC patients treated with first‐line pemetrexed combined with platinum, the low level of blood TCR diversity at baseline with an endpoint of two cycles of chemotherapy was correlated with a poor prognosis. |
topic |
Advanced non‐small cell lung carcinoma T cell diversity tumor microenvironment |
url |
https://doi.org/10.1111/1759-7714.13771 |
work_keys_str_mv |
AT liqian bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy AT zhangzhaohui bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy AT xuyaping bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy AT liuzhentian bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy AT liuzhentao bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy AT wangqiqi bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy AT guyangchun bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy AT liuyane bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy AT yinwencheng bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy AT yifumei bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy AT yaoyanhong bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy AT caobaoshan bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy AT liangli bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy |
_version_ |
1724172920317542400 |